📜 What This Document Is 📄

This is a Form 6-K, which is a standardized report filed with the U.S. Securities and Exchange Commission (SEC). Since Abivax S.A. is a foreign company, this filing allows them to update U.S. investors and regulators on material events that happen back in France. Generally, a 6-K is used to announce things like results, major partnerships, or corporate actions.

👉 Why it matters: This specific filing, dated April 20, 2026, primarily serves to formalize the announcement of an upcoming General Meeting, ensuring U.S. investors know where to look for details.

🏢 About Abivax S.A. 🇫🇷

Abivax S.A. is a pharmaceutical company based in Paris, France. While the filing is highly procedural, it confirms the company's physical location and primary contact details. The company is responsible for developing treatments, likely focusing on advanced therapeutic modalities given the industry.

👉 The filing confirms the principal executive offices are located at 7-11 boulevard Haussmann 75009 Paris, France.

📅 The General Meeting Details 🗓️

The most significant content of this filing is the announcement of a major corporate governance event: the Annual Ordinary and Extraordinary General Meeting. These meetings are where the company's shareholders vote on important decisions, such as electing directors or approving yearly financial reports.

👉 Key Date: The General Meeting is scheduled for May 11, 2026. 👉 The filing notes that a detailed press release (Exhibit 99.1) was published on April 20, 2026, and contains the necessary preparatory documents for this event.

🧑‍💼 Leadership and Management 👨‍🔬

The filing confirms the current executive leadership structure and who was authorized to submit this important report to the SEC. This section confirms the official sign-off on the document.

👉 The filing confirms that Marc de Garidel is the current Chief Executive Officer (CEO) and signed the report on behalf of Abivax SA.

🌐 Reporting Status and Legal Form ⚖️

This section deals with the legal requirements of foreign private issuers. When a company is a "foreign private issuer," it means it operates outside the U.S. but has reporting requirements for U.S. investors. The company must link its filings to other formal, ongoing reports (like Form F-3 and Form S-8).

👉 The inclusion of the formal "Incorporation by Reference" statements means that this 6-K filing legally directs investors to the core, ongoing regulatory documents that truly govern the company.

📞 Key Contacts and Filing Metadata 📧

Although this section lacks business content, it is critical for investors needing to follow up on the filing or for media relations. These details ensure transparency regarding communication channels.

👉 Abivax S.A. Contact:

• Address: 7-11 boulevard Haussmann 75009 Paris, France
• Phone: +33 (0) 1 53 83 08 41

🔮 What's Next: The Road Ahead ⏭️

This filing isn't about current results, but rather setting the timeline for the future. The major focus is the upcoming Annual Ordinary and Extraordinary General Meeting on May 11, 2026.

👉 This date is the key point of reference, signaling when shareholders will have the opportunity to review the year's performance and vote on the company’s future direction.

🧠 The Analogy 💡

Think of a 6-K filing like a company sending a formal "Heads Up" notice to its investors. It doesn't contain the entire novel (the full annual report), but it tells you: "Hey, mark your calendar for May 11th, because that's when the big shareholder meeting is going to happen, and here are the supporting materials you need to read beforehand." It’s a mandatory scheduling alert, not a financial update.

🧩 Final Takeaway 🎯

Abivax is formally notifying the market of a crucial Annual General Meeting on May 11, 2026. Investors must await the preparatory documents, which are now available, to understand the company's corporate decisions and financial standing.